Switch to
View more

Parenteral Drugs (India) Ltd

PDPL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13 cr, stock is ranked 3,249
High RiskStock is 3.39x as volatile as Nifty
4.450.20 (+4.71%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13 cr, stock is ranked 3,249
High RiskStock is 3.39x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
-0.17
PB RatioPB Ratio
-0.02
Dividend YieldDiv. Yield
Sector PESector PE
32.95
Sector PBSector PB
4.55
Sector Div YldSctr Div Yld
0.97%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Parenteral Drugs (India) Limited is a healthcare company. The Company is engaged in the manufacturing of allopathic pharmaceutical preparations.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201920202021202233.4532.1212.2360.78-147.90-114.09-121.72-76.37
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Closure of trading window 
Announced OnJun 30, 2022

Parenteral Drugs (India) Limited has informed the Exchange about Closure of trading window | Download

Parenteral Drugs (India) Limited has informed the Exchange about Closure of trading window | Download

Reply to Clarification Sought- Financial Results 
Announced OnJun 20, 2022

PDPL : The Exchange had sought clarification from Parenteral Drugs (India) Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed. | Download

PDPL : The Exchange had sought clarification from Parenteral Drugs (India) Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed. | Download

Clarification- Financial Results 
Announced OnJun 15, 2022
PDPL : The Exchange has sought clarification from Parenteral Drugs (India) Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
PDPL : The Exchange has sought clarification from Parenteral Drugs (India) Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
See all events